|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NSAIDS CONCURRENT ADMINISTRATION SHOULD BE CAUTIOUS AS THESE INHIBIT PROSTAGLANDIN SECRETIONS WHICH MAY REDUCE THE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
ADDITIVE MYELOSUPPRESSION WHEN USED WITH OTHER MYELOSUPPRESSIVE DRUGS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
NSAIDS INHIBIT SPREADING ACTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY CAUSE CARBACHOL INEFFECTIVE
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
ANTICOAGULANT EFFECT IS INCREASED
|
INCREASED CHANCES OF PERIPHERAL NEUROPATHY
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
PENICILLAMINE CAN CAUSE CHELATION
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|